Comparison of two ketorolac injection methods on complications after third tooth surgery

Comparison of the effectiveness of ketorolac subperiosteal and infiltrate injections into the buccal mucosa in preventing postoperative complications after impacted third molar surgery.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N155

Enrollment

Registered

2020-11-18

Start date

2020-10-06

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impacted teeth. Embedded and impacted teeth

Interventions

Intervention 1: The first intervention group will receive 30 mg of single-dose ketorolac (Alborz Pharmaceutical Company) as a subperiosteal injection immediately after anesthesia injection of the alve

Eligibility

Sex/Gender

All

Age

18 Years to 40 Months

Inclusion criteria

Inclusion criteria: Physical health Presence of an impacted third molar is confirmed by panoramic radiography and is free of infection and pericoronitis No concomitant use of nonsteroidal anti-inflammatory drugs, salicylates, anticoagulants, anticonvulsants, and valprates due to interference with the injectable substance (ketorolac).

Exclusion criteria

Exclusion criteria: Recent use of anti-inflammatory drugs and antibiotics Having underlying diseases such as diabetes, gastrointestinal diseases, etc. Current consumption of drugs, alcohol and opium over the past month Pregnant women

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: Two and 7 days after dental surgery. Method of measurement: Based on visual pain scale.;Trismus. Timepoint: Two and 7 days after dental surgery. Method of measurement: Question from the patient (Low, medium, severe).;Paresthesia. Timepoint: Two and 7 days after dental surgery. Method of measurement: Question from the patient (Low, medium, severe).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrnaz Pourahmadi

Kermanshah University of Medical Sciences

140dent95mehr@gmail.com+98 83 3729 6591

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026